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ABSTRACT 1 
 2 
Spinal neurodegeneration is an important determinant of disability progression in patients 3 
with primary progressive multiple sclerosis (PPMS). Advanced imaging techniques, such as 4 
single-voxel 1H-MR spectroscopy (MRS) and q-space imaging (QSI), have increased 5 
pathological specificity for neurodegeneration, but are challenging to implement in the spinal 6 
cord and have yet to be applied in early PPMS. By combining these imaging techniques with 7 
new clinical measures, which reflect spinal cord pathology more closely than conventional 8 
clinical tests, we explored the potential for spinal MRS and QSI to detect early spinal 9 
neurodegeneration that may be responsible for clinical disability. 10 
Data from We recruited 23 21 PPMS patients within six years of disease onset and 26 24 11 
healthy controls were analysed. Patients were clinically assessed on grip strength, vibration 12 
perception thresholds (VPT) and postural stability, in addition to the Expanded Disability 13 
Status Scale, 9-hole peg test, timed 25-foot walk test, Multiple Sclerosis Walking Scale-12, 14 
and Modified Ashworth Scale (MAS). All subjects underwent MRS and QSI of the cervical 15 
cord and conventional brain and spinal MRI at 3T. Multivariate analyses and multiple 16 
regression models were used to assess the differences in imaging measures between groups 17 
and the relationship between MRI measures and clinical scores, correcting for age, gender, 18 
spinal cord cross-sectional area, brain T2 lesion volume, and brain white matter and grey 19 
matter volume fractions. 20 
 21 
Although patients did not show significant cord atrophy when compared with healthy 22 
controls, they had significantly lower total N-acetyl-aspartate (tNAA) (mean 4.01 versus 5.31 23 
mmol/L, P=0.020) and Glutamate-Glutamine (Glx) (mean 4.65 versus 5.93 mmol/L, 24 
P=0.043) than controls. Patients showed an increase in QSI-derived indices of perpendicular 25 
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diffusivity in both the whole cord and major columns compared with controls (P<0.05 for all 1 
indices). Lower tNAA was associated with higher disability, as assessed by EDSS 2 
(Coefficient= -0.41, 0.01<P<0.05), MAS (Coefficient= -3.78, 0.01<P<0.05), VPT 3 
(Coefficient= -4.37, P=0.021) and postural sway (P<0.001). Lower Glx predicted increased 4 
postural sway (P=0.017). Increased perpendicular diffusivity in the whole cord and columns 5 
was associated with increased scores on the MAS, VPT and postural sway (P<0.05 in all 6 
cases). 7 
 8 
These imaging findings indicate reduced structural integrity of neurons, demyelination, and 9 
abnormalities in the glutamatergic pathways in the cervical cord of early PPMS, in the 10 
absence of extensive spinal cord atrophy. The observed relationship between imaging 11 
measures and disability suggests that early spinal neurodegeneration may underlie clinical 12 
impairment, and should be targeted in future clinical trials with neuroprotective agents to 13 
prevent the development of progressive disability.  14 
  15 
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INTRODUCTION  1 
 2 
The clinical phenotype of primary progressive multiple sclerosis (PPMS) is characterised by 3 
sustained disability progression from disease onset and is typically associated with severe 4 
locomotor disability (Thompson et al., 2000), with a median time to DSS 6 (walking with a 5 
cane) of between 6 to 8.5 years (Runmarker and Andersen, 1993; Cottrell et al., 1999; 6 
Confavreux et al., 2000). The rate of disability progression is highly variable, but occurs 7 
more quickly early in the disease course and reflects, in part, neuroaxonal loss and neuronal 8 
dysfunction in the spinal cord (Bjartmar et al., 2000). There would be great value in 9 
developing and applying imaging markers of neurodegenerative processes to the spinal cord 10 
in early PPMS in order to improve our understanding of the early pathological events that 11 
occur in the injury pathway responsible for clinical disability. This step is considered to be 12 
crucial in the translational pathway that aims to validate biomarkers that predict clinical 13 
outcomes and treatment response in clinical trials in PPMS (Fox et al., 2012). 14 
 15 
Advanced quantitative MRI (qMRI) has been applied in the brain in early PPMS and has 16 
improved our understanding of the mechanisms leading to tissue damage, beyond that 17 
associated with macroscopic T2 lesions (Wheeler-Kingshott et al., 2014). Measures provided 18 
by diffusion tensor imaging (DTI)  and 1H-MR spectroscopy (1H-MRS), have been shown to 19 
correlate with disability (Ramio-Torrenta et al., 2006; Sastre-Garriga et al., 2005; Bodini et 20 
al., 2013), and to predict progression (Khaleeli et al., 2007; Khaleeli et al., 2008). Applying 21 
similar techniques to the spinal cord has been technically challenging (Wheeler-Kingshott et 22 
al., 2014).  However, recent developments have led to applications of advanced qMRI in the 23 
spinal cord in relapsing-remitting multiple sclerosis (RRMS) and have provided insights into 24 
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underlying spinal tissue pathology (Ciccarelli et al., 2007; Farrell et al., 2008; Marliani et al., 1 
2010; Ciccarelli et al., 2013; Kearney et al., 2014).  2 
 3 
One of the most promising qMRI techniques is high b-value Q-space imaging (QSI), a model 4 
free diffusion weighted imaging (DWI) technique (Callaghan et al., 1988). QSI is thought to 5 
be highly specific for axonal injury (Assaf et al., 2005) and has shown better sensitivity for 6 
detecting pathophysiological changes within lesions and normal appearing white matter 7 
(NAWM), compared to DTI in the brains of patients with MS (Assaf et al., 2002). A small 8 
pilot study in relapse-onset MS demonstrated the feasibility of using high b-value QSI in the 9 
spinal cord with improved detection of abnormal diffusion compared with the conventional 10 
DWI acquisition and analysis (Farrell et al., 2008). 11 
 12 
Spinal cord 1H-MRS is used to quantify metabolites which reflect specific pathological 13 
processes, and can complement structural imagingComplementary to structural MRI, is 14 
metabolic imaging, such as spinal cord 1H-MRS, which is used to quantify metabolites that 15 
are markers of specific pathological processes (Ciccarelli et al., 2014). Commonly quantified 16 
metabolites in the spinal cord include: total N-acetyl-aspartate (tNAA), a marker of 17 
neuroaxonal integrity and metabolic function (Moffett et al., 2007), Myo-inositol (Ins), a 18 
marker of astrocytic activation and proliferation (Brand et al., 1993), and total Choline 19 
(tCho), which reflects changes in steady state levels of membrane phospholipids released 20 
during myelin breakdown (Henning et al., 2008; Marliani et al., 2010). More recently, our 21 
group developed a new protocol capable of quantifying glutamate-glutamine (Glx), a marker 22 
of neuronal integrity and neurotransmitter pool, in the spinal cord (Solanky et al., 2013). 23 
Although there have been a few spinal cord MRS studies in patients with RRMS and 24 
neuromyelitis optica (NMO), which have consistently shown neuronal loss and metabolic 25 
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dysfunction, as reflected by reduced concentration in tNAA in the cervical cord of patients 1 
compared to controls (Marliani et al., 2007; Ciccarelli et al., 2007; Ciccarelli et al., 2013), to 2 
date none have included patients with PPMS. 3 
 4 
Besides the need to utilise more pathologically specific in vivo spinal cord imaging 5 
techniques, there is also a need to incorporate objective clinical measures, which are more 6 
sensitive to changes in clinical functions mediated by spinal pathways than conventional 7 
clinical tests, such as the Expanded Disability Severity Scale (EDSS) (Kurtzke, 1983). 8 
Measures such as postural stability, vibration perception thresholds (VPT) and dynamometry 9 
are more responsive to small clinical changes due to damage in the spinal cord than the 10 
EDSS, and have been shown to increase the sensitivity for detecting correlations between 11 
MRI abnormalities in the spinal cord and disability (Zackowski et al., 2009; Oh et al., 2013).  12 
 13 
In the current study we have used a combination of MRS and QSI to investigate changes in 14 
the cervical cord which underlie disability in patients with early PPMS, to test two 15 
hypotheses; i) MRS and QSI demonstrate early neurodegeneration in the upper cervical cord 16 
in patients with PPMS before the occurrence of spinal cord atrophy; ii) in patients, there is a 17 
relationship between MRS and QSI measures and disability, as reflected by newer spinal-18 
cord specific clinical scores, alongside standard MS clinical scales, suggesting that early 19 
spinal cord neurodegeneration is linked with clinical impairment in PPMS. 20 
 21 
 22 
 23 
  24 
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MATERIALS AND METHODS 1 
 2 
Study participants 3 
We prospectively recruited patients with a diagnosis of PPMS (Polman et al., 2005), aged 4 
between 18 – 65 years, within six years from disease onset, as well as, age and gender 5 
matched healthy controls. On the day of the MRI, patients were clinically assessed. All 6 
subjects provided written, informed consent prior to taking part in the study which was 7 
approved by our local research ethics committee. 8 
 9 
Clinical Assessments 10 
All patients were assessed using conventional clinical scales, including the EDSS (Kurtzke, 11 
1983), 9-Hole Peg Test (HPT) (Goodkin et al., 1988) and Timed 25-foot Walk Test (TWT) 12 
(Cutter et al., 1999). For the purpose of statistical analysis, the average of two trials of the 13 
TWT and the average of four trials of the HPT (averaged as reciprocals of the mean times 14 
from two trials for each hand) (Fischer et al., 1999) were calculated. We also used the 15 
Multiple Sclerosis Walking Scale-12 (MSWS-12) (Hobart et al., 2003), and the Modified 16 
Ashworth Scale (MAS) (Bohannon and Smith, 1987). The MAS values from 16 muscle 17 
groups in the upper and lower limbs were converted from a 0–4 scale (which includes a value 18 
of 1+ between scores of 1 and 2) to a 0 –5 scale; the resulting values were summated to 19 
obtain an overall score ranging from 0 to 80 (Stein et al., 2007).   20 
 21 
Clinical scales with the potential to be sensitive to spinal cord pathways injury were also 22 
applied, including the mean grip strength from both upper limbs, using the Jamar hydraulic 23 
dynamometer (Sammons Preston Incorporated, Bolingbrook, IL, USA) (Svens and Lee, 24 
2005), and the vibration perception thresholds (VPTs), which were measured from all four 25 
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limbs at the lateral malleoli and ulna styloid processes using the biosthesiometer (Bio-1 
Medical Instrument Company, Newbury, Ohio). Mean VPTs were calculated and used in the 2 
analysis. Finally, postural stability was assessed using a modified version of a recently 3 
described protocol for quantifying stance instability (Bunn et al., 2013). Subjects were asked 4 
to stand relaxed and still, facing a blank wall at a distance of 1 metre, in a well-lit room, for 5 
40 second-long trials. Three trials under each of the four conditions were recorded, consisting 6 
of 2 stance widths (inter-malleolar distance of 32 cm and 4 cm) under 2 visual conditions 7 
(eyes either open or closed). Body sway was measured using a 3-D orientation sensor (MTx: 8 
Xsens, Enschede, NL), which was fixed to the skin, just below the C7 spinous process. The 9 
device measured the instantaneous angular position of the trunk in the anteroposterior (pitch) 10 
and mediolateral (roll) planes and was sampled at 100Hz. Summary measures were made on 11 
these signals using custom scripts written in Matlab (The Mathworks, Natick, MA USA). The 12 
raw data were low-pass filtered at 10Hz using a zero-phase, 5th order Butterworth filter. The 13 
amount of angular motion was then calculated separately for the roll and pitch body sway 14 
data and from the combined motion given by square root (pitch-motion2 + roll-motion2), 15 
termed total sway. All three signals were summarised by summing the sample-to-sample 16 
absolute change in signal and then dividing by the duration of the trial to yield average 17 
angular speeds of body sway reported in degrees/second. The mean of the three trials per 18 
condition were used for statistical analysis. An index of exacerbation of sway on eye closure 19 
was obtained from the Romberg quotient calculated as sway eyes closed/sway eyes open at 20 
both stance widths. 21 
 22 
 23 
 24 
 25 
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Spinal cord and brain MRI Protocol  1 
All scans were performed using a 3T Achieva system (Philips Medical Systems, Best, 2 
Netherlands). To reduce motion artefacts during scanning and improve image quality, an MR 3 
compatible cervical collar was worn by all volunteers (Yiannakas et al., 2012).   4 
 5 
Using the manufacturer’s 16-channel neurovascular coil (Phillips Healthcare Systems), single 6 
voxel MRS was performed using a recently optimised protocol (Solanky et al., 2013). 7 
Conventional turbo spin-echo sequences (TSE) were used to acquire structural images for 8 
radiological reading and to guide guiding voxel placement. T2w images were acquired in the 9 
coronal plane [parameters: TR = 4000 ms; TE = 100ms; FOV= 160 x 250 mm2; voxel size = 10 
0.6 x 0.6 x 3.0 mm3; NEX = 2; 13 contiguous slices; scan time =1:36 minutes] and PD/T2w 11 
images were acquired in the sagittal plane using a dual echo TSE [parameters: TR = 4000 ms; 12 
TE = 15/80ms; FOV= 256 x 160 mm2; echo train length (ETL) = 12; voxel size = 1.0 x 1.0 x 13 
3.0 mm3; NEX = 2; 12 contiguous slices; scan time = 5:44 minutes]. For spectroscopy, 14 
volumes of interest (VOIs) with dimensions of approximately 5.4 x 7.76 x 55mm3 (2.3 ml) 15 
were prescribed using the reference images and centred on the C2/3 intervertebral disc 16 
(Figure 1). The dimensions of the VOI were adjusted in the anterior-posterior (AP) direction 17 
dependent on the size of each volunteers spinal cord (Ciccarelli et al., 2007; Marliani et al., 18 
2010). MRS data was acquired using a point resolved spectroscopy (PRESS) localisation 19 
sequence [parameters: TE = 30ms; 376 averages with triggered, first order iterative 20 
shimming, multiply optimised insensitive suppression train (MOIST) water suppression, 4 21 
outer volume suppression (OVS) slabs in the AP and rostrocaudal directions and cardiac 22 
gating (TR = 3RR ≈ 3000 ms) using a peripheral pulse unit (350ms delay), scan time = 19:42 23 
minutes]. 24 
 25 
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For cord mean cross-sectional area (CSA) measurements and confirmation of lesion location, 1 
the cervical cord was imaged in the axial plane, perpendicular to the longitudinal axis of the 2 
cord with the imaging volume centred on the C2/3 intervertebral disc, using a fat-suppressed 3 
3D slab-selective fast field echo (FFE) sequence [parameters: TR = 23 ms; TE = 5ms; flip 4 
angle α = 7°; FOV= 240 x 180 mm2; voxel size = 0.5 x 0.5 x 5 mm3; NEX = 8; 11 axial 5 
contiguous slices; scan time = 15:58 minutes]. In order to match the position and orientation 6 
of the volumetric scan to the spectroscopy voxel, the prescription values used for the MRS 7 
acquisition were copied and manually entered by the operator when setting up the 3D-FFE 8 
scan.  9 
 10 
Using the manufacturer’s 32-channel receive head coil (Philips Medical Systems, Best, 11 
Netherlands), each subject underwent a cardiac gated DWI acquisition [parameters: voxel 12 
size=1×1×5 mm3 (interpolated in k-space to a 0.5 x 0.5mm2 in-plane resolution) FOV = 64 × 13 
64mm2; TR = 9RR, TE = 129ms] performed with the volume centred on the C2/C3 disc to 14 
ensure similar coverage as the spectroscopy voxel; 12 axial contiguous slices covering a 15 
60mm length of the cervical cord, typically giving coverage of the C1-3 spinal segments 16 
(Figure 1). The 32 channel head coil was used because it gave superior SNR during QSI 17 
sequence optimisation experiments (Schneider et al., 2011). A ZOOM sequence was used 18 
with outer-volume suppression to minimise artefacts (Wilm et al., 2007). Thirty DWI 19 
volumes with equally spaced 𝐪𝐪-values (Farrell et al., 2008) (Schneider and Wheeler-20 
Kingshott, 2014) and two non-diffusion weighted (b0) volumes were acquired with diffusion 21 
weighting in two perpendicular (x and y) and one parallel (z) direction relative to the main 22 
axis of the spinal cord  [parameters: diffusion pulse duration δ=11.4 ms, diffusion time 23 
Δ=75ms, gradient strength G linearly increased in 31 steps from 0 to 87.5mT/m in x and y 24 
direction and 62mT/m in z direction; scan time = 22:28 minutes].  25 
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 1 
To achieve the maximum possible gradient strength on the scanner, we exploited the 2 
combination of parallel gradient amplifiers in the scanner, which each generate a maximum 3 
diffusion gradient strength of 62mT/m along the major axis of the scanner bore. Assuming 4 
axial symmetry of the axons along the long axis of the spinal cord, we applied gradient 5 
amplifiers in two orthogonal directions that maximise gradient strength perpendicular to axis 6 
of the spinal cord (Supplementary figure 1). This allowed us to generate a guaranteed 7 
maximum gradient strength of √2*62mT/m in the xy direction. In the z direction we use a 8 
maximum gradient of 62 mT/m. q-value were the same in xy and z direction, but the increase 9 
in gradient strength allowed us to use a smaller the gradient pulse duration of 11.4ms in xy 10 
direction (16ms in z). The full protocol is given in supplementary table 1. 11 
 12 
For calculation of brain T2 lesion volumes, PD/T2 weighted images were acquired using a 13 
dual-echo TSE sequence [parameters: TR = 3500 ms; TE = 15/85 ms; flip angle α = 90°; 14 
FOV= 240 x 180 mm2; voxel size = 1 x 1 x 3 mm3; NEX = 1; 50 axial contiguous slices; scan 15 
time = 4:01 minutes]. For calculation of brain tissue volumes a 3D T1-weighted 16 
magnetisation-prepared gradient-echo sequence was used [TR = 6.9 ms; TE = 3.1 ms; TI = 17 
824 ms; flip angle α = 8°; FOV= 256 x 256 mm2; voxel size = 1 x 1 x 1 mm3; NEX = 1; 180 18 
sagittal contiguous slices; scan time = 6:31 minutes].  19 
 20 
Imaging post-processing 21 
 22 
Spinal cord metabolite quantification  23 
Metabolite concentrations were quantified using the user-independent LCModel (version 6.3) 24 
package (Provencher, 1993) and a set of basis spectra, comprising seventeen metabolites 25 
12 
 
including the macromolecules, simulated using GAMMA (Smith et al., 1994) as previously 1 
described (Solanky et al., 2013). NAA (N-acetyl-aspartate) + NAAG (N-acetylaspartyl 2 
glutamate), (hereafter tNAA), tCho (Choline + phosphocholine), tCr (creatine + 3 
phosphocreatine), Ins and Glx concentrations were quantified using the unsuppressed water 4 
signal obtained from the same voxel as a reference (Gasparovic et al., 2006) and formed the 5 
focus of our analysis. Corrections for T2 values were not performed because the TE used is 6 
relatively short, compared to the T2 relaxation times of the metabolites under study 7 
(Wansapura et al., 1999; Edden et al., 2007) and, therefore, it is expected that changes in T2 8 
would be negligible. Measuring T2 values for each metabolite would not have been possible 9 
in a patient cohort within clinically feasible scan times 10 
 11 
The signal-to-noise ratio (SNR) and full width of half maximum (FWHM) of the tNAA peak 12 
provided by LCModel were used to assess spectral quality and Cramér–Rao Lower Bounds 13 
(CRLB) values of <20% for tNAA, tCr, tCho and Ins and <30% for Glx were used to confirm 14 
the reliability of the spectral fit (Provencher, 2014). Poor quality spectra were excluded from 15 
the analysis. Criteria for exclusion were poor water suppression or FWHM > 0.13 with SNR 16 
< 3.   17 
 18 
Spinal cord cross sectional area measurement  19 
Image segmentation and CSA measurements were performed using the 3D-FFE dataset in 20 
Jim 6.0 Software (Xinapse systems, Northants, England). Three contiguous 5mm axial slices, 21 
centred on the C2/3 disc were segmented using the active surface model method (Horsfield et 22 
al., 2010). The mean cross-sectional area of these three slices was then calculated. 23 
 24 
Spinal cord QSI and ROI analysis  25 
13 
 
QSI indices from the q-space analysis, which characterise the diffusion properties of water, 1 
are derived from the displacement probability density function (dPDF), which is the average 2 
probability of a spin moving a certain distance during a given diffusion time. At a given 3 
diffusion time, a tall, narrow dPDF suggests a low diffusion constant and/or restricted 4 
diffusion, whereas a low, broad dPDF suggests a high diffusion constant and/or more 5 
unrestricted diffusion (Farrell et al., 2008).  6 
 7 
The two perpendicular diffusion directions were averaged (xy) to increase the signal-to-noise 8 
ratio. The measurements were then linearly regridded to be equidistant in q-space and the 9 
diffusion dPDF was computed using inverse Fast Fourier Transformation. To increase the 10 
resolution of the dPDF, the signal was extrapolated in q-space to a maximum q=200mm−1 by 11 
fitting a bi-exponential decay curve to the DWI data (Farrell et al., 2008). The dPDF was 12 
computed from the extrapolated DWI data on a voxel-by-voxel basis using the inverse Fast 13 
Fourier Transformation. Supplementary figure 2 illustrates the processing pipeline. 14 
 15 
Data was corrected for motion using reg_aladin from the NiftyReg toolkit (Ourselin et al., 16 
2000). Registration was performed between the interleaved b=0 acquisitions of the xy and z 17 
protocol using the first b=0 of the xy protocol as reference. The estimated registration was 18 
then applied to the intermediate DWI images. The quality of the motion correction was 19 
assessed in each subject and mis-registered slices/subjects were excluded from the study. 20 
 21 
Voxel-wise maps of the full width at half maximum (FWHM), which represents the width of 22 
the dPDF, and the zero displacement probability (P0), representing the height of the dPDF, 23 
were computed for xy and z. Conventional ADC maps were also derived from the low b-24 
14 
 
value part of the decay curve (b < 1100s/mm2) for both xy and z directions, using a 1 
constrained non-linear least squares fitting algorithm (Farrell et al., 2008). 2 
 3 
To assess region specific differences in QSI indices, the whole 60mm length of upper 4 
cervical spinal cord was first extracted from CSF and other tissue types, and four regions of 5 
interest (ROIs) were created using the ROI tool in JIM 6.0 and positioned using the b0 6 
images for each axial slice for orientation. ADC and QSI indices were measured from ROIs 7 
in the anterior, right lateral, left lateral and posterior columns, as well as whole cord 8 
(Supplementary figure 3). No statistical differences were found between QSI indices from 9 
the right and left lateral columns; therefore for ease of analysis, a mean value from both 10 
columns was calculated for each of the QSI indices. 11 
 12 
 13 
Brain T2 Lesion volumes and grey matter and white matter volume fractions 14 
Brain T2-lesion volume (T2LV) was calculated by outlining lesions on T2-weighted MRI 15 
scans using a semi-automated edge finding tool (JIM v. 6.0) by a single observer (KA). Total 16 
lesion volume was recorded in mLs for each subject. 17 
 18 
To avoid segmentation errors due to white matter (WM) lesions, an automated lesion-filling 19 
technique was employed (Chard et al., 2010). Lesion masks were created based on 3D-T1 20 
weighted sequences. The lesion-filled images were segmented into WM, grey matter (GM) 21 
and cerebrospinal fluid (CSF), using the ‘new segment’ option in SPM8 (statistical 22 
parametric mapping; Wellcome Trust Centre for Neuroimaging, University College London 23 
(UCL) Institute of Neurology, London). Segmentations were reviewed to exclude errors. WM 24 
15 
 
and GM fractional (WMF and GMF) volumes, relative to total intracranial volume (the sum 1 
of GM, WM and CSF volumes), were calculated.  2 
 3 
Statistical analysis 4 
Analyses were performed in Stata 13.1 (Stata Corporation, College Station, Texas, USA). 5 
Adjusted differences between patients and controls were obtained by multiple regression of 6 
the relevant imaging measure on a subject type indicator, with age, gender and CSA as 7 
covariates. This analysis was then repeated to evaluate the adjusted difference between 8 
controls and patients with and without spinal cord lesions within the C1-3 region of interest. 9 
In the case of CSA, group differences were obtained with a multiple regression model co-10 
varying for age and gender.  11 
 12 
In patients, univariable associations between metabolites and whole cord QSI metrics were 13 
examined with Pearson correlations. Associations between spinal cord imaging measures and 14 
EDSS, MAS, HPT and VPTs were examined with multiple regression of the clinical variable 15 
on the spinal cord imaging measure as predictor, with the following potential confounders as 16 
covariates: age, gender, mean cord area, brain T2 lesion volume, GMF and WMF; because of 17 
the large number of covariates, these were entered singly into the model, and the unadjusted 18 
association is only reported where it was not materially affected by entering any of these 19 
covariates. Where regression residuals showed signs of non-normality (e.g. for EDSS), the 20 
non-parametric bias corrected and accelerated bootstrap was used (1000 - 5000 replicates, 21 
depending on the p-value resolution required), and then, if more precise determination was 22 
too computer intensive, the P-value was reported as a range.  23 
 24 
16 
 
For associations between spinal cord measures and measures of postural stability, 1 
multivariate regression was used because of the highly related nature of the clinical measures: 2 
by performing joint tests of association, the danger of spurious significant results was 3 
minimised by reporting associations only where the joint test was significant; where the joint 4 
test is not significant, there is no global evidence for any of the individual associations tested, 5 
in which case these are not reported as significant even when individually P<0.05. The 6 
multivariate associations were carried out with potential confounders entered as described 7 
above. 8 
 9 
 10 
11 
17 
 
RESULTS  1 
 2 
Participant demographics and characteristics 3 
 4 
Twenty-three patients with early PPMS and 26 healthy controls were recruited. One patient 5 
was unable to tolerate the scan and was therefore excluded; a second patient’s scans were 6 
excluded from the final analysis due to severe motion-related image degradation. Two control 7 
subjects were also excluded from the study due to the detection of unexpected pathology on 8 
structural spinal cord imaging. Therefore data from 21 patients and 24 age and gender-9 
matched healthy controls were included in the final analysis (Table 1). Patients had short 10 
disease duration and mild to moderate levels of disability; further details on patient 11 
characteristics, disability and conventional brain MRI are summarised in Table 1. 12 
Conventional MRI of the cervical cord identified cervical cord lesions in 18 out of 21 patients 13 
(see conventional MRI findings presented patient-by-patients with age and disease duration 14 
in supplementary Table 12). Of the 18 patients with cervical cord lesions, 142 patients had 15 
lesions within the lower C1 to upper C4 C3 segments covered by the MRS and QSI volumes.  16 
 17 
Spectroscopy quality indicators  18 
Typical post-processed spectra are shown in Figure 2. The FWHM and SNR estimated by 19 
LCModel (reported as mean ± SD) were 0.11 ± 0.03 ppm and 4.4 ± 1.4 respectively. Mean 20 
CRLBs for each metabolites were; tNAA (8%), tCr (11%), tCho (10%), Ins (10%) and Glx 21 
(21%). The reproducibility of MRS measurements achieved with this protocol have 22 
previously been reported (Solanky et al., 2013). 23 
 24 
Differences in spinal cord measures between patients and controls 25 
18 
 
There was no significant difference in CSA between patients and controls, after adjusting for 1 
age and gender (P = 0.092). Patients had lower spinal tNAA and Glx concentrations than 2 
healthy controls, after correction for age, gender and CSA, and this was most marked in 3 
patients with spinal cord lesions within the spectroscopic volume (Table 2 and Figure 2). Ins 4 
concentrations were borderline significantly higher in patients than healthy controls but were 5 
significantly elevated in patients with a C1-C3 lesion (Table 2).  6 
 7 
Patients had significantly higher perpendicular diffusivity (indicating increased movement of 8 
water perpendicular to the main cord axis, as reflected by increased ADCxy and FWHMxy 9 
and reduced P0xy), in the whole cord and the anterior, posterior and lateral columns, and a 10 
significant increase in parallel diffusivity (ADCz) confined to the posterior columns when 11 
compared with controls, after adjusting for age, gender and CSA (Table 2, Table 3 and 12 
Figure 2). Perpendicular diffusivity derived from QSI indices (FWHMxy and P0), but not 13 
ADCxy was also significantly higher in patients with normal appearing spinal tissue 14 
compared with healthy controls (Table 2). 15 
 16 
Univariable analysis of spinal cord metabolite concentrations and QSI metrics in 17 
patients 18 
In patients, spinal cord tNAA concentration was negatively correlated with whole cord 19 
ADCxy (r = - 0.581, p = 0.011) and FWHMxy (r = - 0.636, p = 0.005) and positively 20 
correlated with whole cord P0xy (r = 0.646, p = 0.004) (Supplementary Figure 4). Other 21 
spinal metabolite concentrations did not correlate significantly with each other, or with cord 22 
QSI indices. 23 
 24 
Associations between whole cord imaging measures and clinical disability 25 
19 
 
In patients, following adjustment for age, gender, CSA, brain T2 lesion volume, GMF and 1 
WMF, a significant association was seen between lower spinal tNAA concentrations and 2 
increased global and spinal-cord specific disability measures (as reflected by higher EDSS, 3 
MAS, VPT and postural sway, respectively) (Tables 4 and 5). Lower spinal Glx and higher 4 
Ins were both also independently associated with increased postural instability (Table 5). 5 
When looking at the relationship between QSI measures and disability, increased QSI-6 
derived perpendicular diffusivity was associated with higher spasticity (MAS), higher VPT, 7 
and increased postural instability (Tables 4 and 5). 8 
 9 
Associations between column-specific QSI indices and clinical disability 10 
Following adjustment for age, gender, CSA, brain T2 lesion volume, GMF and WMF, 11 
increased perpendicular diffusivity within the major spinal columns was associated with 12 
increased disability. In particular, increased spasticity was independently associated with 13 
perpendicular diffusivity in all the columns (in particular, lower P0xy in the anterior, lateral 14 
and posterior columns, increased FWHMxy in the anterior and lateral columns, and increased 15 
ADCxy in the lateral columns). Reduced vibration sensation was independently associated 16 
with increased perpendicular diffusivity (reduced P0xy and increased FWHMxy and ADCxy) 17 
in the anterior, lateral and posterior columns. Instability in the roll plane was independently 18 
associated with increased perpendicular diffusivity (reduced P0xy) in the posterior column, 19 
while instability in the pitch plane was independently associated with increased perpendicular 20 
diffusivity (increased ADCxy) in the anterior column. A summary of associations is 21 
presented in Table 6. 22 
 23 
  24 
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Discussion 1 
In this study, we have demonstrated lower concentrations of tNAA and Glx in the upper 2 
cervical cord of patients with early PPMS compared to controls, which suggest the presence 3 
of neurodegeneration, including neuronal loss and/or metabolic dysfunction, and changes in 4 
the glutamatergic pathway. The increased QSI-derived perpendicular diffusivity (increased 5 
FWHMxy and decreased P0xy) in patients compared with controls further confirms the 6 
occurrence of reduced neuronal integrity, possibly with demyelination. Significant 7 
associations between spinal cord tNAA, Glx and QSI-derived perpendicular diffusivity and 8 
newer measures of clinical disability, such as postural stability and VPT, suggest that these 9 
imaging measures reflect abnormalities that contribute to clinical impairment. Thus, the 10 
evidence for early neurodegeneration in the spinal cord, in the absence of extensive spinal 11 
cord atrophy, and its link with clinical impairment, provide insights into the pathological 12 
events that occur in PPMS and indicate that this should become a target for therapeutic 13 
intervention. qMRI measures will be further developed and validated as useful biomarkers of 14 
disease progression and treatment response in clinical trials.  15 
 16 
Differences in metabolite concentrations and QSI measures between patients and 17 
controls 18 
The lower tNAA concentrations in the spinal cord of PPMS patients when compared with 19 
healthy controls are consistent with metabolite abnormalities in the brain, where tNAA is 20 
lower in cortical grey matter and NAWM in early PPMS compared with controls (Sastre-21 
Garriga et al., 2005). In addition, our findings are qualitatively similar to those seen in acute 22 
(Ciccarelli et al., 2007; Henning et al., 2008; Ciccarelli et al., 2010) and chronic (Marliani et 23 
al., 2010; Ciccarelli et al., 2013) spinal cord lesions in RRMS. The majority of the early 24 
21 
 
PPMS patients included in the present study (N=1412) had a lesion (or part of a lesion) 1 
within the spectroscopic voxel and in these patients, spinal tNAA concentrations were lower 2 
than patients without a lesion., suggesting that lesional tissue abnormalities may have 3 
contributed to the observed tNAA changes. There were too few subjects in the study to detect 4 
a statistically significant difference in tNAA concentrations between patients with and 5 
without spinal lesions within the spectroscopic voxel: we estimated that the sample size 6 
required to detect a difference between those two groups with 80% power (alpha 0.05) using 7 
the spectroscopy protocol described in this study would be 168 subjects per group; this 8 
finding suggests that tNAA concentration is the lowest in the lesional tissue of the spinal 9 
cord, but may be reduced, although less extensively, in the normal-appearing white matter 10 
when compared with the healthy tissue, which is similarly to what has been previously been 11 
demonstrated in the brain (Caramanos et al., 2005).  12 
Glx, which represents the sum of Glu and its precursor Gln, was also significantly lower in 13 
patients than controls., These changes were most significant in patients with spinal cord 14 
lesions within the spectroscopic voxel and likely reflecting changes in the spinal 15 
glutamatergic pathway. . Glu makes up the majority of the Glx signal (Baker et al., 2008), 16 
and is predominantly found in the synaptic terminals, with relatively little present in the 17 
extracellular compartment and glial cells (Kaiser et al., 2005; Muhlert et al., 2014). It is 18 
therefore possible that lower spinal Glx could in part, be explained by neuro-axonal 19 
degeneration. In the brains of patients with early PPMS, Glx is reduced in the cortical grey 20 
matter, but not the NAWM (Sastre-Garriga et al., 2005). Similarly, in patients with clinically 21 
stable RRMS, Glu and Glx are both reduced in grey matter regions (Muhlert et al., 2014). 22 
Together these results would suggest that the reductions in Glx reflect reduced synaptic 23 
density in the grey matter secondary to neuronal loss. We found that Glx did not correlate 24 
well with tNAA, which suggests that impairment of glutamatergic metabolism as well as 25 
22 
 
neuroaxonal loss may occur in early PPMS, and these metabolites reflect different aspects of 1 
the underlying tissue changes.  2 
During relapses, Glu is elevated in acute cerebral white matter lesions (Srinivasan et al., 3 
2005) and elevated Glu is associated with accelerated neuronal loss on long-term follow-up 4 
(Baranzini et al., 2010). It has been suggested that activated inflammatory cells are the source 5 
of transient excesses in Glu (Piani et al., 1991), and as inflammation ebbs, Glu concentrations 6 
return to normal (Stover et al., 1997; Gurwitz and Kloog, 1998). 7 
Using QSI we measured diffusivity, parallel and perpendicular to the long axis of the spinal 8 
cord and found significantly higher perpendicular diffusivity in patients compared with 9 
controls. The changes in the dPDF shape (Figure 2) in our patient group are likely to reflect a 10 
breakdown in myelin and axonal membranes which both act as microstructural barriers to 11 
perpendicular diffusion (Beaulieu, 2002) and correspond to what would be expected based on 12 
findings from murine and canine models of dysmyelination and axonal loss (Biton et al., 13 
2006; Farrell et al., 2010; Wu et al., 2011; Anaby et al., 2013), as well as to what has 14 
previously been reported in patients with relapse-onset MS (Assaf et al., 2002; Farrell et al., 15 
2008). The differences in QSI measures between patients and controls are also in agreement 16 
with the tNAA and Glx changes detected and provide corroborating evidence for early 17 
neurodegeneration in the cervical cord. Importantly, in patients with normal appearing spinal 18 
tissue within the diffusion imaging volume, FWHMxy and P0xy remained significantly 19 
different to controls, whereas ADCxy did not, suggesting that QSI indices are more sensitive 20 
to microstructural injury than conventional ADC measures. 21 
In addition to the differences in tNAA, Glx and QSI-derived perpendicular diffusivity 22 
between groups, we found that patients had higher spinal Ins levels than controls but this 23 
finding did not reach statistical significance. However, wWe calculated that for Ins, to have 24 
23 
 
80% power to detect a patient vs control difference of the size observed (which is about two 1 
thirds of a standard deviation) at 5% significance, 40 subjects per group would be necessary. 2 
Patients with a spinal cord lesion within the spectroscopic voxel did have significantly 3 
elevated Ins concentrations, Therefore, the difference in Ins between groupswhich may is 4 
likely to reflect genuine metabolic differences and suggests that astrocytic proliferation and 5 
activation (or gliosis) occurs in the spinal cord lesions in early PPMS. Previous studies have 6 
suggested that gliosis is an early pathological process in MS, and gliosis may be an important 7 
mechanism of disease progression (Ciccarelli et al., 2014). Our results suggest this process is 8 
more active in lesional than non-lesional tissue. 9 
With regard to tCho, which is a marker of inflammation and membrane turnover (Henning et 10 
al., 2008; Marliani et al., 2010), since the observed differences between groups is less than 11 
15% of the SD, it would take hundreds of subjects per arm to detect such a small difference, 12 
suggesting that this metabolite is unlikely to be useful for distinguishing patients from 13 
healthy controls in future studies. 14 
In our study, spinal CSA, a measure of tissue loss, which is often used as an imaging 15 
surrogate of axonal loss and has started to be used in MS clinical trials (Kearney et al., 2013), 16 
was not significantly different between patients and controls despite CSA measurements 17 
being performed on a sequence with high in-plane resolution. Earlier studies with larger 18 
sample sizes (Bieniek et al., 2006) and those which included patients with longer disease 19 
duration (Losseff et al., 1996), demonstrated significant cord atrophy in PPMS. Based on 20 
CSA measures from our cohort of patients and controls, we estimate that the sample size 21 
required to detect significant differences in CSA in early PPMS, using the method described 22 
in this study with 80% power (alpha = 0.05), is 68 subjects per group. This would suggest 23 
that much smaller sample sizes are required to detect group differences early in the disease 24 
course with newer qMRI measures that reflect neurodegenerative processes other than 25 
24 
 
atrophy alone. We cannot exclude that alternative image segmentation methods, such as the 1 
edge detection and partial volume correction method proposed by Tench et al (Tench et al., 2 
2005) may have enabled detection of significant cord atrophy in this patient group and this 3 
merits further study in future. In order to validate these new measures for clinical trials, it is 4 
important to test whether these qMRI measures and metabolite concentrations are sensitive to 5 
changes occurring over time and predict clinical outcome at follow-up. 6 
 7 
Association between spinal cord metabolites and diffusion indices 8 
The modifications to gradients and pulse lengths necessary to perform QSI on clinical 9 
scanners have the effect of exaggerating the contribution of slow diffusing water to QSI 10 
metrics (Assaf et al., 2002), consequently, diffusion of intra-axonal water is highly 11 
represented (Assaf and Cohen, 2000; Assaf et al., 2000; Assaf et al., 2005) and it has 12 
therefore been suggested that QSI metrics make useful markers of axonal integrity. 13 
Interestingly, in our study, spinal tNAA concentration which reflects axonal integrity 14 
correlated more strongly with QSI derived indices of perpendicular diffusivity than ADC 15 
suggesting these indices are more indicative of axonal integrity. 16 
 17 
Associations between whole cord imaging measurements and clinical disability 18 
Using new clinical scales, which reflect disability in functions mediated by spinal cord 19 
pathways, we have extended previous findings of significant associations between tNAA and 20 
neurological disability, as measured by the EDSS, in the spinal cord of RRMS patients 21 
(Ciccarelli et al., 2007; Blamire et al., 2007), by demonstrating that significant associations 22 
exist in patients with early PPMS and that Glx levels are associated with postural stability.  23 
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 1 
We found that, in patients, higher Ins concentrations were associated with poor postural 2 
stability, suggesting that spinal cord gliosis may be a process of clinical importance in early 3 
PPMS. This is in agreement with spinal cord MRS studies in RRMS, which have shown an 4 
increased Ins concentration in patients than controls (Marliani et al., 2010) and a relationship 5 
between higher Ins and higher EDSS scores (Ciccarelli et al., 2007).  6 
 7 
In agreement with the MRS results, we found that increased whole cord QSI-derived 8 
perpendicular diffusivity, which reflects increased movement of water in the direction 9 
perpendicular to the main axis of the cord, as a consequence of reduced neuronal integrity 10 
and/or demyelination, is independently associated with increased spasticity, VPTs and 11 
postural instability. Our findings extend on those from an earlier pilot study which found a 12 
significant increase in QSI-derived perpendicular diffusivity within spinal cord lesions in 13 
patients with relapse-onset MS compared to healthy controls (Farrell et al., 2008), and 14 
suggest that whole cord QSI reflects clinically meaningful pathological changes in the spinal 15 
cord. 16 
 17 
Associations between column-specific diffusion indices and disability 18 
We found several significant associations which were expected based on a priori knowledge 19 
of the neurological function of tracts running in specific spinal cord columns. Specifically, 20 
increased QSI-derived perpendicular diffusivity within the anterior and lateral columns, 21 
where the corticospinal tracts are located, independently predicted spasticity. Instability in the 22 
roll plane and diminished vibration sense were predicted by increased perpendicular 23 
26 
 
diffusivity in the posterior columns, where afferent sensory tracts conveying vibration sense 1 
and proprioception run. It is interesting that this effect emerges with the feet wider apart, 2 
when the body is normally more stable. It has previously been suggested that the increased 3 
stability with increasing stance width, in part, arises from hip proprioceptors being 4 
increasingly able to signal lateral sway, because of the mechanical linkage between hips and 5 
ankles (Day et al., 1993), which may be degraded where there is posterior column pathology. 6 
When we examined the association between the imaging measures and postural stability, we 7 
found that higher ADCxy in the anterior column was associated with increased instability in 8 
the pitch plane, which implies that pitch plane abnormalities are predominantly linked to 9 
pathology of the tracts running in the anterior columns that mediate motor organisation or 10 
coordination. The coordination of joints is probably more demanding in the sagittal (pitch) 11 
plane, since there are more degrees of freedom due to independent action of leg joints. In 12 
contrast, in the frontal (roll) plane, the knees cannot contribute much to instability, while the 13 
ankle and hips are no longer independent (Day et al., 1993).  14 
 15 
For associations between imaging and clinical measures, we did not adjust for multiple 16 
comparisons since we were investigating a number of different hypotheses, and in such 17 
contexts correction can be inappropriate (Rothman, 1990; Perneger, 1998); nevertheless, as 18 
always there is a danger of spurious significant results, and p-values close to 0.05 should be 19 
interpreted with caution, and regarded as hypothesis-generating, to be examined in future 20 
studies. 21 
 22 
Limitations and future directions 23 
27 
 
Although we have used state-of-the-art spinal cord sequences, there are a number of 1 
limitations of the current study that future work could try to address. Using a clinical scanner, 2 
our MRS protocol reliably quantified Glx (Glu + Gln) in the spinal cord for the first time in 3 
an MS patient group. Strategies for separating Glu and Gln at 3T such as TE-averaged 4 
PRESS have been developed and used in the brain (Hurd et al., 2004; Hancu, 2009), but they 5 
may not be feasible in the spinal cord, using a 3T scanner as much larger voxel sizes would 6 
be needed. Future technical developments may make it possible to directly measure Glu with 7 
no Gln overlap in the spinal cord, which would allow a more specific evaluation of the role of 8 
Glu in MS pathophysiology in the spinal cord. 9 
 10 
In addition, the smaller gradients and longer gradient pulses needed to perform QSI on a 11 
clinical scanner have the effect of narrowing the dPDF produced by q-space analysis, 12 
possibly leading to an under-estimate of the FWHM. It has been proposed that these should 13 
be considered as apparent values (Assaf et al., 2005; Farrell et al., 2008). Therefore direct 14 
comparison with previously published studies should be made with care, and only after taking 15 
into account differences in gradient settings. 16 
It was beyond the scope of the current study to establish whether the QSI indices used in this 17 
study are more sensitive to spinal microstructural changes, than the more established DTI-18 
derived indices such as fractional anisotropy (FA), radial (RD) and axial (AD) diffusivity. 19 
AnSome attempts to address this question hasve been made in the past. In 2002, Assaf et al 20 
examined 13 patients with MS using DTI and q-space imaging and demonstrated greater 21 
sensitivity of q-space metrics at detecting abnormalities in the normal appearing white matter 22 
and lesional brain tissue compared with FA (Assaf et al., 2002). This finding was reproduced 23 
in a later study from the same group in 2005 (Assaf et al., 2005), when they also showed that 24 
28 
 
q-space displacement values correlated strongly to NAA/Cr ratios suggesting they are highly 1 
specific for axonal loss. 2 
A future longitudinal extension of the current study will investigate whether QSI and MRS 3 
measures are predictive of disability and cord atrophy at 1 year and 3 years. We will also 4 
examine whether the predictive accuracy can be improved by combing metabolic and 5 
structural metrics into a parametric model. Application of these new imaging techniques to 6 
patients with other MS subtypes is also required. This information may help to stratify 7 
patients for treatments and clinical trials on the basis of their spinal cord pathology and 8 
predicted clinical course. Further work is still needed to establish the relationship between 9 
QSI derived indices from the lateral columns and lateralised disability and to assess how 10 
closely longitudinal changes in imaging measures reflect clinical change in order to validate 11 
the use of these advanced spinal cord imaging protocols to provide potential imaging 12 
biomarkers for future clinical trials of neuroprotective agents.  13 
 14 
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Figure 1: Planning of spectroscopy voxel and DWI volume. Above: sagittal (A) and coronal 1 
(B) T2w images of the cervical cord with spectroscopy voxel centred on C2/3 intervertebral 2 
disc. Below: sagittal (C) and coronal (D) T1w image of the cervical cord showing DWI 3 
volume coverage centred on the C2/3 disc. 4 
 5 
 6 
Figure 2: Differences in height and width of the dPDF from the posterior and lateral columns 7 
between a healthy control and patient are shown on the far left. Grouped P0xy maps, 8 
FWHMxy maps and post-processed spectra from 3 controls (central) and 3 patients (far right) 9 
demonstrate lower probability of zero net displacement (P0xy) and increased diffusion 10 
distribution (FWHMxy) in the patients. The spectra show reduced tNAA and Glx levels in 11 
the patients compared to the controls. 12 
 13 
Supplementary figure 1: Illustration of gradient direction scheme used for x and y QSI 14 
encoding. The QSI gradient directions are chosen to maximise the diffusion encoding 15 
gradient strength in the perpendicular plane to the spinal cord (red arrows). 16 
 17 
Supplementary figure 2: Q-space imaging processing pathway. From top left to bottom right: 18 
The raw data points per voxel are re-gridded and then extrapolated using a bi-exponential fit. 19 
The inverse Fourier transformation is performed to give the probability density function, 20 
from which summary statistics are derived. 21 
 22 
Supplementary figure 3: Axial b0 image of the cervical spinal cord showing the location of 23 
regions of interest (ROIs) placed in the anterior (A), right lateral (R), left lateral (L) and 24 
posterior (P) columns. After ROI’s were drawn on the b0 images, they were overlaid onto the 25 
QSI and ADC maps. 26 
 27 
 28 
Supplementary figure 4: Scatter graphs showing correlation between spinal tNAA 29 
concentration and whole cord P0xy (left), FWHMxy (centre) and ADCxy (right) 30 
 31 
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 Healthy Controls 
(n = 24) 
PPMS Patients 
(n = 21) 
Mean age (SD) 42.1 (11.5) years 48 (7.9) years 
Gender 19F: 5M 12F: 9M 
Mean CSA (SD) 81.8 (8.1) mm2 77.5 (9.6) mm2 
Mean GMVF (SD) 0.48 (0.01) 0.47 (0.01) 
Mean WMVF (SD) 0.34 (0.01) 0.33 (0.01) 
Mean brain parenchymal fraction (SD) 0.82 (0.02) 0.80 (0.02) 
Mean T2 lesion volume (SD)  11.6 (9.4) ml 
Mean disease duration (SD)  3.9 (1.5) years 
Median EDSS (range)  5.0 (3.0 - 6.5) 
Mean TWT (SD)  8.1 (5.9) seconds 
Mean MSWS-12 (SD)  44.4 (11.4) 
Mean summated MAS (SD)  7.2 (9.3) 
Mean HPT (SD)  30.0 (13.3) seconds  
Mean grip strength (SD)  50.2 (26.4) lbs force 
Mean vibration perception threshold (SD)  10.7 (10.6) 
Mean sway, 32cm, EO (SD)   0.87 (0.37) deg/s 
Mean sway, 32cm, EC (SD)  1.07 (0.46) deg/s 
Mean sway, 4cm, EO (SD)   0.98 (0.38) deg/s 
Mean sway, 4cm, EC (SD)  1.28 (0.58) deg/s 
 1 
 2 
 3 
 4 
Table 1: Demographic, clinical and radiological characteristics of patients and volunteers 5 
  6 
Abbreviations:  9 hole peg test (HPT); 25ft timed walk test (TWT); Cord surface area (CSA); Expanded 
disability status scale (EDSS); Eyes closed (EC); Eyes open (EO); Grey matter volume fraction (GMVF); 
Modified Ashworth score (MAS); MS walking scale (MSWS); Standard deviation (SD); White matter 
volume fraction (WMVF). 
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 1 
Metabolite  Healthy Controls 
(n = 24) 
Patients without 
C1-3 lesion 
(n = 9) 
Patients with 
C1-3 lesion 
(n= 12) 
All Patients 
(n = 21) 
 
tNAA  
(mmol/L) 
5.31 (1.47) 4.23 (0.86) 
P=0.206 
3.89 (1.31) 
P=0.102 
4.01 (1.16) 
P=0.020 
 
 
tCho 
(mmol/L)  
1.31 (0.41) 1.12 (0.22) 
P=0.241 
1.33 (0.38) 
P=0.852 
1.26 (0.34) 
P=0.610 
 
tCr 
(mmol/L) 
 
3.76 (1.13) 3.04 (0.35) 
P=0.099 
4.22 (1.73) 
P=0.908 
3.79 (1.48) 
P=0.963 
 
Ins 
(mmol/L) 
4.49 (1.23) 4.25 (1.17) 
P=0.287 
6.26 (1.84) 
P=0.006 
5.55 (1.88) 
P=0.081 
 
Glx 
(mmol/L) 
5.93 (1.66) 5.01 (1.90) 
P=0.170 
4.50 (0.71) 
P=0.047 
4.65 (1.11) 
P=0.043 
 
ADCxy        
(µm2/ms) 
0.390 (0.09) 0.421 (0.05) 
P=0.151 
0.481 (0.10) 
P=0.002 
0.454 (0.08) 
P=0.006 
 
ADCz          
(µm2/ms) 
1.783 (0.10) 0.183 (0.01) 
P=0.123 
0.183 (0.02) 
P=0.119 
1.834 (0.14) 
P=0.123 
 
FWHMxy    
(µm x 102) 
0.236 (0.02) 0.251 (0.01) 
P=0.020 
0.276 (0.04) 
P<0.001 
0.265 (0.03) 
P=0.001 
 
FWHMz      
(µm x 102) 
0.550 (0.03) 0.553 (0.03) 
P=0.427 
0.560 (0.03) 
0.019 
0.557 (0.03) 
P=0.120 
 
P0xy            
(a.u) 
0.202 (0.02) 0.188 (0.01) 
P=0.025 
0.174 (0.03) 
0.001 
0.180 (0.02) 
P=0.001 
 
P0z              
(a.u) 
0.113 (0.004) 0.112 (0.003) 
P=0.278 
0.113 (0.004) 
P=0.481 
0.113 (0.004) 
P=0.470 
 
 2 
 3 
 4 
 5 
 6 
 7 
Abbreviations:  total N-acetylaspartate (tNAA); Choline containing compounds (tCho); myo-Inositol (Ins); 
Glutamate-Glutamine (Glx); Creatine + phosphocreatine (tCr). P values obtained using a linear regression 
analysis, correcting for age, gender and CSA. 
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Table 2: Summary of mean (SD) metabolite concentrations and QSI indices from the cervical 1 
cord of patients and controls and P-values for adjusted group comparisons after correcting for 2 
age, gender and mean cord cross-sectional area. 3 
 4 
 5 
 6 
 7 
  8 
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Region of 
interest 
Diffusion measure PPMS Patients 
(n=21) 
Healthy 
Controls 
(n=24) 
P-value 
Anterior  
Column 
ADCxy        (µm2/ms) 0.497 (0.15) 0.388 (0.12) 0.028 
ADCz          (µm2/ms) 1.921 (0.20) 1.867 (0.17) 0.331 
FWHMxy    (µm x 102) 0.266 (0.04) 0.229 (0.02) 0.001 
FWHMz      (µm x 102) 0.562 (0.03) 0.600 (0.04) 0.159 
P0xy            (a.u) 0.180 (0.03) 0.210 (0.02) 0.002 
P0z              (a.u) 0.111 (0.004) 0.111 (0.01) 0.411 
Posterior 
Column 
ADCxy        (µm2/ms) 0.458 (0.16) 0.368 (0.10) 0.017 
ADCz          (µm2/ms) 2.181 (0.26) 2.092 (0.14) 0.050 
FWHMxy    (µm x 102) 0.261 (0.06) 0.229 (0.03) 0.029 
FWHMz      (µm x 102) 0.610 (0.04) 0.602 (0.04) 0.122 
P0xy            (a.u) 0.185 (0.03) 0.208 (0.03) 0.018 
P0z              (a.u) 0.102 (0.004) 0.103 (0.004) 0.045 
Mean 
Lateral 
Columns 
ADCxy        (µm2/ms) 0.416 (0.11) 0.319 (0.10) 0.001 
ADCz          (µm2/ms) 1.989 (0.26) 1.979 (0.12) 0.581 
FWHMxy    (µm x 102) 0.254 (0.04) 0.214 (0.02) < 0.001 
FWHMz      (µm x 102) 0.579 (0.02) 0.579 (0.03) 0.318 
P0xy            (a.u) 0.189 (0.03) 0.224 (0.03) < 0.001 
P0z              (a.u) 0.108 (0.007) 0.106 (0.004) 0.757 
 1 
Table 3: Summary of mean (SD) Q-space imaging (QSI) indices and apparent diffusion 2 
coefficients (ADC) from the major white matter columns of patients and controls.  P-values 3 
given for adjusted group comparisons after correcting for age, gender and CSA.  4 
40 
 
Abbreviations:  9 hole peg test (HPT); Choline containing compounds (tCho); Expanded disability status scale (EDSS); Modified Ashworth score  (MAS); MS walking scale 
(MSWS);  total N-acetylaspartate (tNAA). 
 
Table 4: Associations between whole cord measures (predictors) and clinical scores (response variables). Unstandardised regression 
coefficients for imaging measures are reported with 95% confidence intervals and p-values. The regression models were adjusted for 
age, gender and mean cord area.  * Bootstrap P-values. 
 
Clinical Score Spinal Cord Measure Regression Coefficient 95 % Confidence Interval P-value 
EDSS tNAA -0.41 -1.06, 0.34 0.01 < P < 0.05 * 
Summated MAS tNAA 
P0xy 
FWHMxy 
ADCxy 
-3.78 
-283.72 
191.30 
63.64 
-16.49, 2.16 
-444.26, -123.19 
86.36, 269.24 
18.89, 103.39 
0.01 < P < 0.05 * 
0.002 
0.001 
0.008 
Mean grip P0xy 435.96 -61.67, 933.59 0.081 
Vibration perception 
threshold 
tNAA 
P0xy 
FWHMxy 
ADCxy 
-4.37 
-344.27 
226.49 
88.06 
-8.08, -0.66 
-512.61, -175.93 
115.73, 337.26 
49.02, 127.10 
0.021 
0.001 
0.001 
< 0.001 
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 Sway                           
Coefficient  (95% CI; P-
value) 
Pitch                            
Coefficient  (95% CI; P-
value) 
Roll                                        
Coefficient  (95% CI; P-
value) 
Romberg Quotient    
Coefficient  (95% CI; P-
value) 
tNAA P < 0.001 
4EO: -0.057 (-0.188, 0.074; P = 0.393) 
4EC: -0.192 (-0.416, 0.033; P = 0.094) 
32EO: -0.072 (-0.118,-0.022; P = 0.004) 
32EC: -0.086 (-0.221, 0.048; P = 0.208) 
P < 0.0001 
4EO: -0.036 (-0.144, 0.073; P = 0.517) 
4EC: -0.137 (-0.277, 0.003; P = 0.056) 
32EO: -0.047 (-0.099, 0.006; P = 0.082) 
32EC: -0.063 (-0.192, 0.066; P = 0.338) 
P = 0.005 
4EO: -0.039 (-0.111, 0.033; P = 0.286) 
4EC: -0.103 (-0.256, 0.049; P = 0.184) 
32EO: -0.044 (-0.069,-0.018; P = 0.001) 
32EC: -0.046 (-0.083,-0.009; P = 0.014) 
P  = 0.003 
4cm: -0.112 (-0.191,-0.033; P = 0.006) 
32cm: -0.191 (-0.123, 0.085; P = 0.718) 
 
Glx P = 0.017 
4EO: -0.171 (-0.301, -0.042; P = 0.010) 
4EC: -0.320 (-0.564, -0.076; P = 0.010) 
32EO: -0.057 (-0.127, 0.014; P = 0.114) 
32EC: -0.163 (-0.310,-0.015; P = 0.031) 
P < 0.001 
4EO: -0.110 (-0.227, 0.007; P = 0.065) 
4EC: -0.204 (-0.360, -0.049; P = 0.010) 
32EO: -0.033 (-0.103, 0.038; P = 0.366) 
32EC: -0.134 (-0.279, 0.010; P = 0.069) 
P = 0.012 
4EO: -0.108 (-0.171, -0.046; P = 0.001) 
4EC: -0.207 (-0.367, -0.046; P = 0.012) 
32EO: -0.039 (-0.076,-0.002; P = 0.039) 
32EC: -0.062 (-0.104, 0.020; P = 0.004) 
P  < 0.0001 
4cm: -0.134 (-0.236,-0.032; P = 0.010) 
32cm: -0.140 (0.232,-0.048; P = 0.003) 
 
Ins P < 0.0001 
4EO: 0.062 (-0.061, 0.185; P = 0.324) 
4EC: 0.100 (-0.102, 0.303; P = 0.332) 
32EO: 0.019 (-0.065, 0.103; P = 0.660) 
32EC: 0.090 (-0.010, 0.191; P = 0.078) 
P = 0.014 
4EO: 0.068 (-0.324, 0.170; P = 0.184) 
4EC: 0.062 (-0.078, 0.201; P = 0.388) 
32EO: 0.026 (-0.045, 0.097; P = 0.477) 
32EC: 0.093 (0.004, 0.183; P = 0.040) 
P = 0.440 P = 0.046 
4cm: 0.031 (-0.052, 0.113; P = 0.467) 
32cm: 0.086 (-0.019, 0.153; P = 0.012) 
 
Cho P = 0.545 P = 0.144 P = 0.979 P = 0.113 
Cr P = 0.306 P = 0.237 P = 0.821 P = 0.363 
42 
 
ADCxy  4EC: 2.48 (0.44, 4.51; P = 0.017) 32EO: 0.93 (0.34, 1.52; P = 0.002) 
32EC: 1.24 (0.28, 2.21; P = 0.011) 
4cm: 1.41 (0.24, 2.59; P = 0.023) 
FWHMxy  4EC: 5.57 (0.02, 11.12; P = 0.049) 32EO: 2.25 (0.56, 3.94; P = 0.009)  
P0xy   32EO: -3.80 (-6.14, -1.46; P = 0.001) 
32EC: -5.01 (-8.84,-1.18; P = 0.010) 
 
Abbreviations:  regression coefficient (Coef.); 95% confidence interval (CI); total N-acetylaspartate (tNAA); Choline containing compounds (tCho); myo-Inositol (Ins); 
Glutamate-Glutamine (Glx); Creatine + phosphocreatine (Cr); Stance width of 32cm, eyes open (32EO); Stance width of 32cm, eyes closed (32EC); Stance width of 4cm, eyes 
open (4EO); Stance width of 4cm, eyes closed (4EC) 
 
Table 5: Associations between whole cord imaging measures and truncal stability. A multivariate analysis was used to assess associations 
between metabolite predictors and the multiple stability scores as response variables. P-values <0.05 for the joint test of the metabolite predictor 
are shown in bold. Metabolite regression coefficients, 95% confidence intervals and p-values are shown for the individual stability variables, and 
these are only shown where the joint test was significant. The regression models adjusted for age, gender and mean cord area. 
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Clinical Score Region of interest Diffusion Measure Regression Coefficient 95 % Confidence Interval P-value 
Summated MAS Lateral Column 
 
 
Anterior Column 
 
Posterior Column 
P0xy 
FWHMxy 
ADCxy 
P0xy 
FWHMxy 
P0xy 
-205.16 
171.80 
50.66 
-185.96 
157.38 
-136.56 
-322.34, -87.97 
91.34, 252.27 
16.50, 84.83 
-316.30, -55.62 
64.03, 250.72 
-267.09, -6.03 
0.002 
< 0.001 
0.006 
0.008 
0.002 
0.04 
Vibration Lateral Column 
 
 
Anterior Column 
 
 
Posterior Column 
P0xy 
FWHMxy 
ADCxy 
P0xy 
FWHMxy 
ADCxy 
P0xy 
FWHMxy 
ADCxy 
-268.54 
223.44 
67.20 
-239.01 
200.74 
40.73 
-219.76 
101.77 
46.29 
-421.03, -116.05 
125.91, 320.90 
28.07, 106.33 
-384.52, -93.50 
106.07,295.41 
7.82, 73.64 
-353.71, -85.80 
32.47, 171.08 
22.24, 70.34 
0.002 
< 0.001 
0.002 
0.003 
0.001 
0.02 
0.003 
0.007 
0.001 
32EO Sway Anterior Column ADCxy 0.81 0.12, 1.50 0.021 
32EO Roll Posterior Column  P0xy -2.16 -4.07, -0.26 0.026 
32EO Pitch  Anterior Column ADCxy 0.69 0.15, 1.23 0.013 
32EC Roll Posterior Column P0xy -3.85 -6.58, -1.12 0.006 
32EC Pitch Anterior Column ADCxy 1.04 0.12, 1.94 0.026 
4EO Pitch Anterior Column ADCxy 1.02 0.13, 1.91 0.025 
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Table 6:  Showing associations between column-specific diffusion indices (predictors) and clinical scores (response variable). 
Unstandardised regression coefficients for imaging measures are reported with 95% confidence intervals and p-values. The regression 
models were adjusted for age, gender and mean cord area. 
 
 
 
 
 
 
4EC Pitch Anterior Column ADCxy 1.54 0.47, 2.63 0.005 
4cm Romberg  Lateral Column ADCxy 1.18 0.20, 2.16 0.023 
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